It was an on-again, off-again couple of weeks for one of the world’s largest drug makers.
On Aug. 13, the U.S. Court of Appeals for the D.C. Circuit suspended the Food and Drug Administration’s decision to approve generic versions of Eloxatin, a cancer drug manufactured by Paris-based Sanofi-Aventis that generated $1.9 billion in worldwide sales last year. By Tuesday, the suspension was called off, meaning that Sanofi’s competitors were free to start shipping and marketing their copies of the medication in the United States.
